Toggle menu

4AT Study

Start date:
August 2015
End date:
Predicted June 2017
Co-ordinated by:
EMERGE team on behalf of University of Edinburgh and NHS Lothian
Main trial site:

The 4AT as a triage test for delirium: a validation study in acutely hospitalised older patients.


To determine the diagnostic accuracy of the 4AT for delirium versus the reference standard of a DSM-IV diagnosis

Trial Design

Patients undergo a standard delirium assessment, and either the 4AT or the Confusion Assessment Method (CAM). Clinical outcomes and resource utilisation are recorded at 12 weeks after admission.

Eligibility criteria

Patients aged over 70 admitted to the Emergency Department.

Chief Investigator

Professor Alasdair MacLullich

Professor of Geriatric Medicine

Research Team

Allan MacRaild

Stroke Lead Research Nurse

Jill Steven

Senior Research Nurse - 4AT study

Mia Paderanga

Senior Research Nurse

Megan McGrath

Senior Research Nurse

Emma Ward

Research Administrator

Related news

4AT team attends British Geriatric Society conference

4AT team attends British Geriatric Society conference

5 Nov 2015 | Allan MacRaild

Emerge sent two research nurses to the British Geriatric Society (BGS) conference. Jill Steven and Allan MacRaild are recruiting to a study entitled The 4AT as a triage test for delirium: a validation study in acutely hospitalised older patients. This study is a first collaboration between Emerge and Medicine of the Elderly with this study being led by Professor Alasdair MacLullich.

Read more
A study to assess a tool to diagnose Delirium

More EMERGE Trials

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX Trial

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more